Download presentation
Presentation is loading. Please wait.
1
Plasma Exchange Chan King Chung
2
History Begins in the 1970s Initially to treat anti-GBM disease
Blood cell separators Initially to treat anti-GBM disease Lowering circulating antibody Widespread use in different condition Some indication replaced by other method Selective extraction for hypercholesterolemia IVIg for immunotherapy
3
Indications Removal of ‘evil’ humoral substances Antibodies
Goodpasture’s Syndrome (Anti-GBM) Wegener Granulomatosis (ANCA) Myasthensia Gravis (Anti-AChR) Toxins Triglycerides Paraproteins Thyroxin Acetylsalicylate Cytokines Sepsis Uncertain Thrombotic Thrombocytopenic Purpura Haemolytic Uraemic Syndrome Guillain-Barre´ syndrome Miller Fisher syndrome Liver failure
4
Physiology of Body Fluid
ECF (27%) 19L Plasma (4 - 5%) 3L Interstitial (12%) 8L RBC (2 – 3.5%) Non-water mass ICF (33%) 23L (40%)
5
Dosage Blood volume 7% of BW Plasma volume ~4% of BW (40mL/kg)
Residual plasma volume = e-(volume removed) Change of 1 plasma volume = 37% remain
6
Dosage Usual 1-1.3x plasma volume per session
Volume = (1- Hct) x 70mL x BW x 1 or 1.3 ~2 to 3L in most case
7
Dosage Frequency of Plasma Exchange depends on
Distribution of substance Rate of production ~5 plasma volume in 7 to 10 days will remove ~90% of the plasma substance
8
Techniques of Plasma Exchange
Access: large vein ± dialysis catheter Anticoagulation Cell Separator Centrifugation Membrane plasma filtration Replacement Fresh frozen plasma Albumin Colloid / Crystalloid
9
Anticoagulation Heparin Citrate 2000 to 5000 units bolus then
500 to 2000 units/hour Citrate
10
Cell Separator Centrifugation 600mL in 37 mins
11
Cell Separator Membrane filtration
12
Performance of Prisma TPE
13
Replacement Post-filter FFP Contain all component
Replacement of specific factor (TTP / Liver failure) Risk of transfusion Citrate Toxicity ? Giving back the ‘Evil’ humoral
14
Composition of Plasma Water Electrolytes Proteins
Na, Cl, Ca, K, PO4, Mg Osmotic pressure of 5526 mmHg Between ECF and ICF Proteins Albumin, Globulins, Complements, Transport Protein, etc. Oncotic pressure of 25 mmHg Distribution between plasma & interstitial fluid
15
Replacement Albumin Expensive Risk of hypokalemia and hypocalcaemia
Risk of bleeding Risk of Prion diseases Mixing electrolyte with 5% albumin solution before use (in paediatrics)
16
Albumin Replacement e- ECF (27%) 19L Plasma (4 - 5%) 3L Interstitial
RBC (2 – 3.5%) Non-water mass ICF (33%) 23L (40%) e-
18
Replacement Colloids HES / Gelofusin Cheaper compare with Albumin
Safer Problem with oncotic pressure Slowly loosing oncotic pressure -> hypovolaemia Pulmonary edema Problem with electrolyte / bleeding
19
Colloid Replacement ECF (27%) 19L Plasma (4 - 5%) 3L Interstitial
RBC (2 – 3.5%) Non-water mass ICF (33%) 23L (40%) H20
20
Colloid Replacement Risk of hypovolaemia balanced by
Higher volume of replacement Close monitoring Risk of pulmonary edema is low Normal oncotic pressure is ~25mmHg Theoretical risk of pulmonary edema when oncotic pressure is <10mmHg
21
Colloid Replacement Studies using HES (t1/2: 8hr) instead of albumin had demonstrated the safety of colloid Journal of Clinical Apheresis. 12(3):146-53, 1997 Less data is available for using gelatin (e.g. gelofusine t1/2: 2hr) Usually when Albumin > 30g/L
22
Replacement Crystalloid Crystalloid-only replacement is not used
Half crystalloid, half albumin regime is commonly used for saving money ~1/3 of crystalloid stay in intravascular space Bolus of crystalloid may be given for hypotension
23
Typical Replacement Full volume gelatin Half gelatin then half albumin
Resulting Alb level 25g/dL Half gelatin then half FFP Full volume FFP For TTP
24
Electrolyte Replacement
Hypokalemia might occur 3L plasma only contain mmol K Large reserve inside the cells Hypocalcaemia 3L plasma contain 6–7 mmol Ca ~10ml 10%CaCl2 Especially if Total Albumin replacement (Ca mmol/L) Cannot clear citrate (as anticoagulation / FFP / Albumin)
25
Setup 3L Session (3hr) Anticoagulation (ACDA 240mL/hr) Replacement
Blood ( mL/min) Plasma (1L/hr)
30
Adverse Reaction Hypotension Hypovolaemia Hypocalcaemia
Allergic reaction ACEI Membrane activation Prekallikrine activator in SPPF
31
Adverse Reaction Bleeding tendency Immunosuppression
Lowered coagulation factors in underlying bleeding disease (TTP) Immunosuppression Lost of immunoglobulins, complements
32
Modification of Plasma Exchange
Coupled Plasma Filtration Adsorption Plasma Filter Charcoal
33
How are we going to do ? By Haematology as much as possible Prisma TPE
AK10
34
Prisma TPE More correct monitoring of volume
Automatically stop removal pump when the replacement is empty Safer Unfamiliar Higher cost
35
Prisma TPE Setting Haematocrit Blood flow rate
Replacement bottle volume Replacement volume Replacement rate Net patient plasma removal rate ** Net plasma removal volume **
36
Prisma TPE 3L Session (3hr) Anticoagulation (ACDA 240mL/hr)
Replacement (1L/hr) Blood ( mL/min) Plasma [1L/hr]+[0mL/hr]
37
? Fluid Gain 240mL/hr for 3 hours 720mL over 3 hours
A small volume only. Can be handled by kidney Useful to counter act hypotension In theory, may set 80mL/hr net loss, as only 1/3 is in intravascular space
38
AK10 Cheaper and more familiar Same setup as CVVH
Only 1 replacement pump and 1 filtrate pump Volume state less accurate than Prisma Risk of hypovolaemia if the replacement pump stopped
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.